{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:15:11Z","timestamp":1790745311420,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T00:00:00Z","timestamp":1455062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T00:00:00Z","timestamp":1455062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>During the latest outbreak of Ebola virus disease in West Africa, monoclonal antibody therapy (e.g., ZMapp) was utilized to treat patients. However, due to the antigenic differences among the five ebolavirus species, the current therapeutic monoclonal antibodies are only effective against viruses of the species <jats:italic>Zaire ebolavirus<\/jats:italic>. Although this particular species has indeed caused the majority of human infections in Central and, recently, West Africa, other ebolavirus species (e.g., <jats:italic>Sudan ebolavirus<\/jats:italic> and <jats:italic>Bundibugyo ebolavirus<\/jats:italic>) have also repeatedly caused outbreaks in Central Africa and thus should not be neglected in the development of countermeasures against ebolaviruses. Here we report the generation of an ebolavirus glycoprotein-specific monoclonal antibody that effectively inhibits cellular entry of representative isolates of all known ebolavirus species <jats:italic>in vitro<\/jats:italic> and show its protective efficacy in mouse models of ebolavirus infections. This novel neutralizing monoclonal antibody targets a highly conserved internal fusion loop in the glycoprotein molecule and prevents membrane fusion of the viral envelope with cellular membranes. The discovery of this highly cross-neutralizing antibody provides a promising option for broad-acting ebolavirus antibody therapy and will accelerate the design of improved vaccines that can selectively elicit cross-neutralizing antibodies against multiple species of ebolaviruses.<\/jats:p>","DOI":"10.1038\/srep20514","type":"journal-article","created":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T10:56:12Z","timestamp":1455101772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Discovery of an antibody for pan-ebolavirus therapy"],"prefix":"10.1038","volume":"6","author":[{"given":"Wakako","family":"Furuyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Nanbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Haddock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Noyori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayato","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,10]]},"reference":[{"key":"BFsrep20514_CR1","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(10)60667-8","volume":"377","author":"H Feldmann","year":"2011","unstructured":"Feldmann, H. & Geisbert, T. W. Ebola haemorrhagic fever. Lancet 377, 849\u2013862 (2011).","journal-title":"Lancet"},{"key":"BFsrep20514_CR2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/1348-0421.12181","volume":"58","author":"K Changula","year":"2014","unstructured":"Changula, K., Kajihara, M., Mweene, A. S. & Takada, A. Ebola and Marburg virus diseases in Africa: increased risk of outbreaks in previously unaffected areas? Microbiol. Immunol. 58, 483\u2013491 (2014).","journal-title":"Microbiol. Immunol."},{"key":"BFsrep20514_CR3","first-page":"1229","volume":"159","author":"JH Kuhn","year":"2014","unstructured":"Kuhn, J. H. et al. Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch. Virol. 159, 1229\u20131237 (2014).","journal-title":"Arch. Virol."},{"key":"BFsrep20514_CR4","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1404505","volume":"371","author":"S Baize","year":"2014","unstructured":"Baize S. et al. Emergence of Zaire Ebola virus disease in Guinea. N. Engl. J. Med. 371, 1418\u20131425 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep20514_CR5","doi-asserted-by":"crossref","first-page":"12463","DOI":"10.1128\/JVI.76.24.12463-12472.2002","volume":"76","author":"SA Jeffers","year":"2002","unstructured":"Jeffers, S. A., Sanders, D. A. & Sanchez, A. Covalent modifications of the Ebola virus glycoprotein. J. Virol. 76, 12463\u201312472 (2002).","journal-title":"J. Virol."},{"key":"BFsrep20514_CR6","doi-asserted-by":"crossref","first-page":"5762","DOI":"10.1073\/pnas.95.10.5762","volume":"95","author":"VE Volchkov","year":"1998","unstructured":"Volchkov, V. E., Feldmann, H., Volchkova, V. A. & Klenk, H. D. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc. Natl. Acad. Sci. USA 95, 5762\u20135767 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep20514_CR7","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1073\/pnas.93.8.3602","volume":"93","author":"A Sanchez","year":"1996","unstructured":"Sanchez, A., Trappier, S. G., Mahy, B. W., Peters, C. J. & Nichol, S. T. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl. Acad. Sci. USA 93, 3602\u20133607 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep20514_CR8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1097-2765(00)80159-8","volume":"2","author":"W Weissenhorn","year":"1998","unstructured":"Weissenhorn, W., Carf\u00ed, A., Lee, K.-H., Skehel, J. J. & Wiley, D. C. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol. Cell. 2, 605\u2013616 (1998).","journal-title":"Mol. Cell."},{"key":"BFsrep20514_CR9","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1128\/JVI.80.8.4174-4178.2006","volume":"80","author":"K Schornberg","year":"2006","unstructured":"Schornberg, K. et al. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J. Virol. 80, 4174\u20134178 (2006).","journal-title":"J. Virol."},{"key":"BFsrep20514_CR10","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2217\/fvl.09.56","volume":"4","author":"JE Lee","year":"2009","unstructured":"Lee, J. E. & Saphire, E. O. Ebolavirus glycoprotein structure and mechanism of entry. Future Virol. 4, 621\u2013635 (2009).","journal-title":"Future Virol."},{"key":"BFsrep20514_CR11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrmicro2764","volume":"10","author":"JM White","year":"2012","unstructured":"White, J. M. & Schornberg, K. L. A new player in the puzzle of filovirus entry. Nat. Rev. Microbiol. 10, 317\u2013322 (2012).","journal-title":"Nat. Rev. Microbiol."},{"key":"BFsrep20514_CR12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","volume":"514","author":"X Qiu","year":"2014","unstructured":"Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47\u201353 (2014).","journal-title":"Nature"},{"key":"BFsrep20514_CR13","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1073\/pnas.1200409109","volume":"109","author":"JM Dye","year":"2012","unstructured":"Dye, J. M. et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Natl. Acad. Sci. USA 109, 5034\u20135039 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep20514_CR14","doi-asserted-by":"crossref","first-page":"e36192","DOI":"10.1371\/journal.pone.0036192","volume":"7","author":"A Marzi","year":"2012","unstructured":"Marzi, A. et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS ONE 7, e36192 (2012).","journal-title":"PLoS ONE"},{"key":"BFsrep20514_CR15","doi-asserted-by":"crossref","first-page":"199ra113","DOI":"10.1126\/scitranslmed.3006608","volume":"5","author":"J Pettitt","year":"2013","unstructured":"Pettitt, J. et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci. Transl. Med. 5, 199ra113 (2013).","journal-title":"Sci. Transl. Med."},{"key":"BFsrep20514_CR16","doi-asserted-by":"crossref","first-page":"18030","DOI":"10.1073\/pnas.1213709109","volume":"109","author":"GG Olinger","year":"2012","unstructured":"Olinger, G. G. et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc. Natl. Acad. Sci. USA 109, 18030\u201318035 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep20514_CR17","doi-asserted-by":"crossref","unstructured":"McCarthy, M. US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ 349, (2014).","DOI":"10.1136\/bmj.g5488"},{"key":"BFsrep20514_CR18","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMoa1409838","volume":"371","author":"GM Lyon","year":"2014","unstructured":"Lyon, G. M. et al. Clinical care of two patients with Ebola virus disease in the United States. N. Engl. J. Med. 371, 2402\u20132409 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep20514_CR19","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/1060028014561227","volume":"49","author":"BM Bishop","year":"2015","unstructured":"Bishop, B. M. Potential and emerging treatment options for Ebola virus disease. Ann. Pharmacother. 49, 196\u2013206 (2015).","journal-title":"Ann. Pharmacother."},{"key":"BFsrep20514_CR20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.annemergmed.2014.10.009","volume":"65","author":"L Meyers","year":"2015","unstructured":"Meyers, L., Frawley, T., Goss, S. & Kang, C. Ebola virus outbreak 2014: clinical review for emergency physicians. Ann. Emerg. Med. 65, 101\u2013108 (2015).","journal-title":"Ann. Emerg. Med."},{"key":"BFsrep20514_CR21","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1128\/CVI.00170-10","volume":"17","author":"E Nakayama","year":"2010","unstructured":"Nakayama, E. et al. Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin. Vaccine Immunol. 17, 1723\u20131728 (2010).","journal-title":"Clin. Vaccine Immunol."},{"key":"BFsrep20514_CR22","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.vaccine.2006.09.076","volume":"25","author":"A Takada","year":"2007","unstructured":"Takada, A., Ebihara, H., Jones, S., Feldmann, H. & Kawaoka, Y. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 25, 993\u2013999 (2007).","journal-title":"Vaccine"},{"key":"BFsrep20514_CR23","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1128\/JVI.77.2.1069-1074.2003","volume":"77","author":"A Takada","year":"2003","unstructured":"Takada, A. et al. Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J. Virol. 77, 1069\u20131074 (2003).","journal-title":"J. Virol."},{"key":"BFsrep20514_CR24","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.sbi.2009.05.004","volume":"19","author":"JE Lee","year":"2009","unstructured":"Lee, J. E. & Saphire, E. O. Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. Curr. Opin. Struct. Biol. 19, 408\u2013417 (2009).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"BFsrep20514_CR25","doi-asserted-by":"crossref","first-page":"e1001121","DOI":"10.1371\/journal.ppat.1001121","volume":"6","author":"A Nanbo","year":"2010","unstructured":"Nanbo, A. et al. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog. 6, e1001121 (2010).","journal-title":"PLoS Pathog."},{"key":"BFsrep20514_CR26","doi-asserted-by":"crossref","first-page":"6481","DOI":"10.1128\/JVI.03156-14","volume":"89","author":"M Kuroda","year":"2015","unstructured":"Kuroda, M. et al. The interaction between TIM-1 and NPC1 is important for the cellular entry of Ebola virus. J. Virol. 89, 6481\u20136493 (2015).","journal-title":"J. Virol."},{"key":"BFsrep20514_CR27","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.vaccine.2013.01.025","volume":"31","author":"L Both","year":"2013","unstructured":"Both, L. et al. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine 31, 1553\u20131559 (2013).","journal-title":"Vaccine"},{"key":"BFsrep20514_CR28","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1086\/514298","volume":"179","author":"K Mupapa","year":"1999","unstructured":"Mupapa, K. et al. Colebunders, J. J. Muyembe-Tamfum, Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J. Infect. Dis. 179 Suppl 1, S18\u201323 (1999).","journal-title":"J. Infect. Dis."},{"key":"BFsrep20514_CR29","unstructured":"WHO Ebola R&D - Monday, 20 July 2015, News on vaccines, therapies, diagnostics (http:\/\/www.who.int\/medicines\/ebola-treatment\/WHO-Ebola-RandD-Newsletter-July.pdf?ua=1) (2015)."},{"key":"BFsrep20514_CR30","first-page":"138ra181","volume":"4","author":"X Qiu","year":"2012","unstructured":"Qiu, X. et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med. 4, 138ra181 (2012).","journal-title":"Sci. Transl. Med."},{"key":"BFsrep20514_CR31","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1038\/srep03365","volume":"3","author":"X Qiu","year":"2013","unstructured":"Qiu, X. et al. Kobinger, Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci. Rep. 3, 3365 (2013).","journal-title":"Sci. Rep"},{"key":"BFsrep20514_CR32","doi-asserted-by":"crossref","first-page":"S410","DOI":"10.1093\/infdis\/jiv209","volume":"212","author":"H Hernandez","year":"2015","unstructured":"Hernandez, H. et al. Development and characterization of broadly cross-reactive monoclonal antibodies against all known Ebolavirus species. J. Infect. Dis. 212 Suppl 2, S410\u2013413 (2015).","journal-title":"J. Infect. Dis."},{"key":"BFsrep20514_CR33","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1371\/journal.ppat.0030009","volume":"3","author":"WB Oswald","year":"2007","unstructured":"Oswald, W. B. et al. Neutralizing antibody fails to impact the Course of Ebola vrus infection in monkeys. PLoS Pathog. 3, e9 (2007).","journal-title":"PLoS Pathog."},{"key":"BFsrep20514_CR34","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1038\/srep06881","volume":"4","author":"J Audet","year":"2014","unstructured":"Audet, J. et al. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Sci. Rep. 4, 6881 (2014).","journal-title":"Sci. Rep"},{"key":"BFsrep20514_CR35","doi-asserted-by":"crossref","first-page":"10982","DOI":"10.1128\/JVI.01490-15","volume":"89","author":"E Davidson","year":"2015","unstructured":"Davidson, E. et al. Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb and MB-003 cocktail antibodies. J. Virol. 89, 10982\u201310992 (2015).","journal-title":"J. Virol."},{"key":"BFsrep20514_CR36","doi-asserted-by":"crossref","first-page":"S372","DOI":"10.1093\/infdis\/jiv303","volume":"212","author":"O Reynard","year":"2015","unstructured":"Reynard, O. & Volchkov, V. E. Characterization of a novel neutralizing monoclonal antibody against Ebola virus GP. J. Infect. Dis. 212 Suppl 2, S372\u2013378 (2015).","journal-title":"J. Infect. Dis."},{"key":"BFsrep20514_CR37","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1126\/science.287.5458.1664","volume":"287","author":"JA Wilson","year":"2000","unstructured":"Wilson, J. A. et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287, 1664\u20131666 (2000).","journal-title":"Science"},{"key":"BFsrep20514_CR38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature07082","volume":"454","author":"JE Lee","year":"2008","unstructured":"Lee, J. E. et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454, 177\u2013182 (2008).","journal-title":"Nature"},{"key":"BFsrep20514_CR39","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/nsmb.2150","volume":"18","author":"JM Dias","year":"2011","unstructured":"Dias, J. M. et al. A shared structural solution for neutralizing ebolaviruses. Nat. Struct. Mol. Biol. 18, 1424\u20131427 (2011).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"BFsrep20514_CR40","doi-asserted-by":"crossref","first-page":"17182","DOI":"10.1073\/pnas.1414164111","volume":"111","author":"CD Murin","year":"2014","unstructured":"Murin, C. D. et al. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc. Natl. Acad. Sci. USA 111, 17182\u201317187 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep20514_CR41","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1021\/cb5006454","volume":"9","author":"G Chen","year":"2014","unstructured":"Chen, G. et al. Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge. ACS Chem. Biol. 9, 2263\u20132273 (2014).","journal-title":"ACS Chem. Biol."},{"key":"BFsrep20514_CR42","doi-asserted-by":"crossref","first-page":"e1003312","DOI":"10.1371\/journal.ppat.1003312","volume":"9","author":"P Pal","year":"2013","unstructured":"Pal, P. et al. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog. 9, e1003312 (2013).","journal-title":"PLoS Pathog."},{"key":"BFsrep20514_CR43","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1371\/journal.pmed.0030237","volume":"3","author":"J Ter Meulen","year":"2006","unstructured":"Ter Meulen, J. et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 3, e237 (2006).","journal-title":"PLoS Med."},{"key":"BFsrep20514_CR44","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1128\/JVI.79.14.9062-9068.2005","volume":"79","author":"AB Bakker","year":"2005","unstructured":"Bakker, A. B. et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J. Virol. 79, 9062\u20139068 (2005).","journal-title":"J. Virol."},{"key":"BFsrep20514_CR45","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1086\/515386","volume":"178","author":"M Bray","year":"1998","unstructured":"Bray, M., Davis, K., Geisbert, T., Schmaljohn, C. & Huggins, J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178, 651\u2013661 (1998).","journal-title":"J. Infect. Dis."},{"key":"BFsrep20514_CR46","doi-asserted-by":"crossref","first-page":"14764","DOI":"10.1073\/pnas.94.26.14764","volume":"94","author":"A Takada","year":"1997","unstructured":"Takada, A. et al. A system for functional analysis of Ebola\u2009virus\u2009glycoprotein. Proc. Natl. Acad. Sci. USA 94, 14764\u201314769 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep20514_CR47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jviromet.2007.02.004","volume":"143","author":"S Shahhosseini","year":"2007","unstructured":"Shahhosseini, S. et al. Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens. J. Virol. Methods 143, 29\u201337 (2007).","journal-title":"J. Virol. Methods"},{"key":"BFsrep20514_CR48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/356083a0","volume":"356","author":"R Luthy","year":"1992","unstructured":"Luthy, R., Bowie, J. U. & Eisenberg, D. Assessment of protein models with three-dimensional profiles. Nature 356, 83\u201385 (1992).","journal-title":"Nature"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep20514.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep20514","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep20514.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T02:50:17Z","timestamp":1672887017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep20514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,10]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,4,22]]}},"alternative-id":["BFsrep20514"],"URL":"https:\/\/doi.org\/10.1038\/srep20514","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,10]]},"assertion":[{"value":"30 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20514"}}